To determine if the serum free light chain (FLC) ratio has prognostic value in patients with symptomatic multiple myeloma (MM), baseline serum samples from a well-characterized cohort of 790 newly diagnosed MM patients were tested with the FLC assay. FLC ratio was calculated as j/k (reference range 0.26-1.65). On the basis of the distribution of values, a cutpoint j/k FLC ratio of o0.03 or 432 was chosen for further analysis. Overall survival was significantly inferior in patients with an abnormal FLC ratio of o0.03 or 432 (n ¼ 479) compared with those with an FLC ratio between 0.03 and 32 (n ¼ 311), with median survival of 30 versus 39 months, respectively. We incorporated abnormal FLC ratio with the International Staging System (ISS) risk factors (that is, albumin o3.5 g/dl and serum b 2 -microglobulin X3.5 g/l), to create a risk stratification model with improved prognostic capabilities. Patients with 0, 1, 2 or 3 adverse risk factors had significantly different overall survival, with median survival times of 51, 39, 30 and 22 months, respectively (Po0.001). These findings suggest that the serum FLC ratio at initial diagnosis is an important predictor of prognosis in myeloma, and can be incorporated into the ISS for improved risk stratification.
Introduction
Multiple myeloma (MM) is a malignant plasma cell disorder, which is diagnosed in over 17 000 patients each year in the United States. 1 The prognosis of these patients is highly variable and depends on age, stage and a number of independent risk factors. [2] [3] [4] In 2005, the International Myeloma Working Group proposed an International Staging System (ISS) based on serum b 2 microglobulin (Sb2M) and albumin. 5 Relying on these simple serum protein measurements, the ISS resulted in three groups of patients with median survivals of 62, 44 and 29 months.
The serum free light chain (FLC) ratio is a readily available laboratory test that has independent prognostic significance in monoclonal gammopathy of undetermined significance, solitary plasmacytoma and smoldering myeloma. [6] [7] [8] The purpose of this study was to determine the prognostic value of the baseline serum FLC ratio in patients with newly diagnosed, symptomatic MM.
Materials and methods

Study cohort
We used a well-characterized cohort of 1027 newly diagnosed, symptomatic MM patients seen at Mayo Clinic from January 1, 1985 through December 31, 1998 to ensure extensive followup. 9 Archived serum samples from blood drawn within 30 days of initial diagnosis were available for the serum FLC assay on 790 of the 1027 patients; blood samples were obtained prospectively from treatment-naïve patients prior to initiation of therapy. Follow-up was through the review of each patient's complete medical records at the Mayo Clinic (including correspondence). The study was approved by the Mayo Institutional Review Board.
Serum FLC assay
Aliquots from the original blood draw were stored at À80 1C and thawed immediately prior to FLC analysis, which was performed by immunonephelometry using specific antibodies (the binding site) on a BNII nephelometer (Dade Behring, Deerfield, Illinois, USA). [10] [11] [12] The FLC assay measures free k (reference interval, 0.33-1.94 mg/dl) and free l (reference interval, 0.57-2.63 mg/ dl) light chains. 13 It allows the assessment of clonality based on the FLC ratio, which is calculated as k/l, that is, free k concentration divided by free l (reference interval, 0.26-1.65). 12 For clinically interpretative purposes, a k/l FLC ratio of o0.26 is defined as having clonal l FLC, that is, l is the involved light chain; similarly, a ratio of 41.65 is defined as having clonal k involvement.
Statistical analysis
Calculations were performed using SAS version 9.1 (SAS Institute Inc., Cary, NC) and Splus version 7.0 (Insightful Corporation, Seattle, WA). Survival was defined as the time from initial diagnosis to death or last follow-up and was estimated according to the Kaplan-Meier method; 14 survival curves were compared using the log-rank test. 14, 15 The prognostic ability of potential risk factors was evaluated in univariate and multivariate models using Cox proportional hazards regression analysis. All statistical tests were two-sided, and P-values of less than 0.05 were considered to be significant.
Results
Sera from a cohort of 1027 previously described MM patients 9 were analyzed for k and l FLC levels that were correlated with existing data for these patients to assess the utility of FLC in predicting prognosis. Of the original 1027 patients, 790 had serum available from frozen aliquots of samples obtained prior to treatment and within 30 days of initial diagnosis. The characteristics of these 790 patients (Table 1) are similar to the characteristics of the overall original cohort (not shown). The median age at diagnosis was 66 years (range, 20-92 years). Over 80% had Durie-Salmon 16 stage III disease. The median duration of follow-up to date is 8.4 years; so far, 655 (83%) of the 790 patients have died.
The FLC ratio was outside of the reference interval (range 0.26-1.65) in 95.1% of the patients ( Table 1 ). The median involved k and l concentrations were 37.1 and 71.3 mg/dl, respectively, with an overall median (k or l) of 49.4 mg/dl. The FLC ratio was chosen for analysis to normalize any effects that freezing and storage of the samples might have had on the absolute light chain concentrations. Sb2M and albumin concentrations obtained at the time of diagnosis were used to determine the ISS stage in all patients for whom those values were known (576 of 790 patients; 72.9%).
FLC ratio predicts overall survival
The relationship of k/l FLC ratio with survival and the corresponding hazard ratios are shown ( Table 2 ). A few patients (n ¼ 39, 4.9%) had FLC ratios within the normal reference range and are included for comparison. As normal FLC ratios were uncommon, an FLC ratio outside of the reference range was not statistically significant as a predictor of poor prognosis. Analysis of a series of progressively wider FLC ratio cutoffs (for example, 0.25-4, 0.125-8, etc.) demonstrated increasingly more significant differences in overall survival (data not shown). A k/l FLC ratio cutoff of o0.03 (alternatively expressed as o1/32) or 432 was chosen for further analysis based on its separation of the cohort into two groups of roughly comparable size (Table 2) . Overall survival was significantly inferior in patients with an FLC ratio of o0.03 or 432 (n ¼ 479 patients) compared with those with an FLC ratio that was between 0.03 and 32 (n ¼ 311 patients), with median survival of 30 versus 39 months, respectively (Po0.001, Figure 1a ). Similar results were obtained when the analysis was performed excluding those patients with light-chain-only multiple myeloma or those patients with renal failure as evidenced by serum creatinine 42 mg/dl (not shown). Use of k or l concentration rather than the FLC ratio provides comparable prediction of overall survival: those patients whose involved FLC level was higher than the median for the group, had a hazard ratio of 1.3 for values above either the overall median, or the k-specific or l-specific medians (Table 2) .
Eighty-seven patients had involved FLC levels greater than 500 mg/dl (45g/l). The prognostic value of the FLC ratio remained unchanged when the analysis was repeated after excluding these patients. Overall survival was significantly inferior in patients with an FLC ratio of o0.03 or 432 (n ¼ 393 patients) compared with those with an FLC ratio that was between 0.03 and 32 (n ¼ 245 patients), with median survival of 30 versus 39 months, respectively (Po0.001). Similarly, results were unchanged after excluding two patients who had FLC values greater than 5000 mg/dl (450 g/l).
FLC ratio adds to current staging systems
The selected FLC ratio cut-point (o0.03 or 432) is comparable with ISS stage in univariate analysis (Table 3) . When combined with ISS stage in a multivariate model, an abnormal FLC ratio added significantly (P ¼ 0.029) to the prognostic capacity of the ISS; this remained significant even with addition of creatinine to the multivariate model (P ¼ 0.027). Use of k or l concentration rather than the FLC ratio provides similar results, with statistically significant improvement over the ISS alone for values above the overall and k-specific or l-specific median (P ¼ 0.016 and P ¼ 0.034, respectively; not shown). Interestingly, the FLC ratio made the most significant contribution to predicting prognosis in ISS stage II patients (n ¼ 265), separating this category into two groups: those with FLC ratio of o0.03 or 432 had a 5-year survival rate of 20.5% (median 30 months, n ¼ 152), as compared with a 5-year survival rate of 35.2% (median 40 months, n ¼ 113) for those ISS stage II patients with a FLC ratio between 0.03 and 32 (P ¼ 0.02, Table 4 ). This suggests that the FLC ratio might have the most benefit in managing those patients who fall into the intermediate category of the ISS.
Risk stratification model
To better study the prognostic ability of readily available laboratory tests, we included serum FLC and the variables used in the ISS as three factors in a risk stratification model. Specifically, abnormal FLC ratio (o0.03 or 432), high Sb2M (X3.5 g/l) or low serum albumin (o3.5 g/dl) were defined as adverse risk factors. Patients with any combination of 0, 1, 2 or 3 adverse risk factors according to the above criteria had significantly different overall survival and hazard ratios. Median survival in patients with three risk factors was less than half that in patients with 0 factors (median survival times of 51, 39, 30 and 22 months for 0, 1, 2 or 3 factors, respectively), whereas the hazard ratio increased to 2.3 in patients with three risk factors (Po0.001, Table 5 and Figure 1b ). This segregation of the highest risk population of patients is superior to the performance of the ISS alone, which estimated a hazard ratio of 1.9 for stage III patients (Table 3) .
Discussion
An abnormal k/l FLC ratio indicates an excess of one light chain type versus the other, and is interpreted as a surrogate for clonal expansion based on extensive testing in normal volunteers and patients with MM, amyloidosis and renal dysfunction. 10, 12 The FLC assay is performed on automated chemistry analyzers, is widely available, and is commonly used to monitor patients with oligo-secretory or nonsecretory myeloma, primary amyloidosis or light-chain-only multiple myeloma 10, 11, 17 The FLC ratio has already shown value in estimating prognosis in monoclonal gammopathy of undetermined significance, solitary plasmacytoma and smoldering myeloma. [6] [7] [8] Unlike monoclonal gammopathy of undetermined significance, in which the FLC ratio is abnormal in approximately one-third of patients, almost all patients with MM have an abnormal FLC ratio. In monoclonal gammopathy of undetermined significance, an incremental prognostic effect is seen with increasing FLC ratios, and those patients with an FLC ratio outside the laboratory reference range (0.26-1.65) have significantly poorer prognosis. In smoldering myeloma, a slightly wider cut-point range (0.125-8) shows the best separation of high-risk and low-risk patients. In this study, an FLC ratio of o0.03 or 432 provided the best separation of groups for prognostic use, by separating the cohort into roughly comparable groups in terms of sample size.
Recently, Kyrtsonis et al. have described the use of serum FLC concentrations to predict prognosis independently of the ISS, in a relatively small group of MM patients with few deaths during 5 years of follow-up. 18 A study by van Rhee et al. confirmed that the baseline FLC ratio was predictive of survival within the first two years after diagnosis. 19 We addressed a similar question in a large cohort of well-described MM patients with extensive follow-up. The data presented here confirm the serum FLC ratio as an independent prognostic variable in MM, suggest that FLC measurement improves upon use of the ISS staging, identifies risk groups based on Sb2M, albumin and the k/l FLC ratio. It is also worth nothing that, because the patients included in this study underwent a variety of therapies, these findings need validation in specific cohorts, such as those patients undergoing high-dose therapy or transplantation.
The FLC assay is undoubtedly a useful test for clinicians dealing with dysproteinemias, both in estimation of prognosis at diagnosis and in monitoring patient progress. Necessarily, on-going studies are pursuing the questions of the best means of reporting FLC data (for example, k/l ratio versus absolute Abbreviation: FLC,free light chain.
Free light chain ratio in multiple myeloma CLH Snozek et al levels) and the utility of FLC testing after initiation of therapy. The findings reported by van Rhee and colleagues suggest that alterations in FLC levels after initiation of treatment may not correlate intuitively with response to therapy. 19 Large, long-term studies will be required to determine the most appropriate interpretation of intra-individual changes in FLC during the course of the disease.
In this study, we found that a subset of patients has high values of FLC, greater than 500 mg/dl. However, the study results were unchanged when the analysis was repeated after excluding these patients. We see such high values sometimes in clinical practice as well, and often there is an accompanying measurable M protein in serum protein electrophoresis. If there is no heavy chain expression on serum immunofixation, one can assume that the serum M protein reflects free monoclonal light chains. But if immunofixation reveals heavy chain expression, one cannot determine whether the serum M spike is FLC or intact immunoglobulin. Occasionally, there may not be a serum M protein detected despite a high FLC value and in some of these cases, it is possible that the FLC is migrating in the b or a regions and is masked by the normal a or b migrating proteins. One must also be aware of other technical issues that cause erroneously high FLC values because the standardization procedures for the FLC test are different from the standardization procedures used for serum protein electrophoresis. In addition, there may be issues with the effect of serial dilutions that are required in the presence of high values that may exaggerate results. We recommend using the FLC ratio cut-points that we have shown to be prognostic in this paper, as their use will limit the impact that very high values can have on results. In clinical practice, physicians should be aware of these issues. In general, for monitoring large monoclonal light chains, we still prefer simultaneous estimation of the 24 h urine protein electrophoresis.
The findings presented here support the addition of the FLC ratio to the risk markers currently used in the ISS. All three are routine, readily available laboratory tests that are already obtained for MM patients in most clinical practices. Thus, little or no additional testing is needed to incorporate these findings into routine practice. The inclusion of baseline FLC ratio into the ISS needs to be validated in a multi-center study, but these data suggest that the estimation of prognosis of newly diagnosed MM patients will be notably improved by including FLC ratio, albumin and Sb2M in a single staging system.
